Myriad Genetics Inc., of Salt Lake City, said the FDA approved BRACAnalysis CDx for use as a companion diagnostic by health care professionals to identify patients with HER2-negative metastatic breast cancer who have a germline BRCA mutation and are candidates for treatment with the PARP inhibitor Lynparza (olaparib), marketed by Astrazeneca plc, of London, and Merck & Co. Inc., of Kenilworth, N.J.